Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Roberts Website

David D. Roberts, Ph.D.

Selected Publications

1)  Kaur S, Singh SP, Elkahloun AG, Wu W, Abu-Asab MS, Roberts DD.
CD47-dependent immunomodulatory and angiogenic activities of extracellular vesicles produced by T cells.
Matrix Biol. 2014.
2)  Cook KL, Soto-Pantoja DR, Abu-Asab M, Clarke PA, Roberts DD, Clarke R.
Mitochondria directly donate their membrane to form autophagosomes during a novel mechanism of parkin-associated mitophagy.
Cell Biosci. 4: 16, 2014.
3)  Rogers NM, Seeger F, Garcin ED, Roberts DD, Isenberg JS.
Regulation of soluble guanylate cyclase by matricellular thrombospondins: implications for blood flow.
Front Physiol. 5: 134, 2014.
4)  Soto-Pantoja DR, Shih HB, Maxhimer JB, Cook KL, Ghosh A, Isenberg JS, Roberts DD.
Thrombospondin-1 and CD47 signaling regulate healing of thermal injury in mice.
Matrix Biol. 2014.
5)  Roberts DD, Frazier WA.
Keeley FW, Mecham RP, eds.
Thrombospondins and Their Receptors: Evolving Functions. In: Evolution of Extracellular Matrix.
New York: Springer; 2013. p. 221-242 [Book Chapter]
6)  Soto-Pantoja DR, Ridnour LA, Wink DA, Roberts DD.
Blockade of CD47 increases survival of mice exposed to lethal total body irradiation.
Sci Rep. 3: 1038, 2013.
7)  Soto-Pantoja DR, Kaur S, Miller TW, Isenberg JS, Roberts DD.
Leukocyte surface antigen CD47.
Signaling Gateway. Apr 19, 2013.
Full Text Article. [Journal]
8)  Navarathna DH, Munasinghe J, Lizak MJ, Nayak D, McGavern DB, Roberts DD.
MRI confirms loss of blood-brain barrier integrity in a mouse model of disseminated candidiasis.
NMR Biomed. 26: 1125-34, 2013.
9)  Soto-Pantoja DR, Stein EV, Rogers NM, Sharifi-Sanjani M, Isenberg JS, Roberts DD.
Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47.
Expert Opin. Ther. Targets. 17: 89-103, 2013.
10)  Miller TW, Kaur S, Ivins-O'Keefe K, Roberts DD.
Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation.
Matrix Biol. 32: 316-24, 2013.
11)  Kaur S, Soto-Pantoja DR, Stein EV, Liu C, Elkahloun AG, Pendrak ML, Nicolae A, Singh SP, Nie Z, Levens D, Isenberg JS, Roberts DD.
Thrombospondin-1 Signaling through CD47 Inhibits Self-renewal by Regulating c-Myc and Other Stem Cell Transcription Factors.
Sci Rep. 3: 1673, 2013.
12)  Roberts DD, Soto-Pantoja DR, Isenberg JS.
CD47. In: Encyclopedia of Signaling Molecules. Volume Part 4.
New York: Springer; 2012. p. 335-343 [Book Chapter]
13)  Soto-Pantoja DR, Roberts DD.
Choi S, eds.
Thrombospondin-1. In: Encyclopedia of Signaling Molecules. Volume Part 21.
New York: Springer; 2012. p. 1846-1852 [Book Chapter]
14)  Rogers NM, Yao M, Zimmerman MW, Roberts DD, Isenberg JS.
Zudaire E, Cuttitta F, eds.
Ex vivo and In vivo Assessments of Angiogenesis, Blood Flow and Vasoactive Capability. In: The Textbook of Angiogenesis and Lymphangiogenesis: Methods and Applications.
New York: Springer; 2012. p. 349-374 [Book Chapter]
15)  Rogers NM, Yao M, Novelli EM, Thomson AW, Roberts DD, Isenberg JS.
Activated CD47 regulates multiple vascular and stress responses: implications for acute kidney injury and its management.
Am. J. Physiol. Renal Physiol. 303: F1117-25, 2012.
16)  Rogers NM, Roberts DD, Isenberg JS.
Age-Associated Induction of Cell Membrane CD47 Limits Basal and Temperature-Induced Changes in Cutaneous Blood Flow.
Ann. Surg. 258: 184-91, 2012.
17)  Soto-Pantoja DR, Miller TW, Pendrak ML, DeGraff WG, Sullivan C, Ridnour LA, Abu-Asab M, Wink DA, Tsokos M, Roberts DD.
CD47 deficiency confers cell and tissue radioprotection by activation of autophagy.
Autophagy. 8: 1628-42, 2012.
18)  Martin-Manso G, Navarathna DH, Galli S, Soto-Pantoja DR, Kuznetsova SA, Tsokos M, Roberts DD.
Endogenous thrombospondin-1 regulates leukocyte recruitment and activation and accelerates death from systemic candidiasis.
PLoS ONE. 7: e48775, 2012.
19)  Miller TW, Wang EA, Gould S, Stein EV, Kaur S, Lim L, Amarnath S, Fowler DH, Roberts DD.
Hydrogen sulfide is an endogenous potentiator of T cell activation.
J. Biol. Chem. 287: 4211-21, 2012.
20)  Soto-Pantoja DR, Miller TW, Frazier WA, Roberts DD.
Inhibitory signaling through signal regulatory protein-a is not sufficient to explain the antitumor activities of CD47 antibodies.
Proc. Natl. Acad. Sci. U.S.A. 109: E2842; author reply E2844-5, 2012.
21)  Englund EA, Wang D, Fujigaki H, Sakai H, Micklitsch CM, Ghirlando R, Martin-Manso G, Pendrak ML, Roberts DD, Durell SR, Appella DH.
Programmable multivalent display of receptor ligands using peptide nucleic acid nanoscaffolds.
Nat Commun. 3: 614, 2012.
22)  Roberts DD, Miller TW, Rogers NM, Yao M, Isenberg JS.
The matricellular protein thrombospondin-1 globally regulates cardiovascular function and responses to stress via CD47.
Matrix Biol. 31: 162-9, 2012.
23)  Navarathna DH, Lionakis MS, Lizak MJ, Munasinghe J, Nickerson KW, Roberts DD.
Urea amidolyase (DUR1,2) contributes to virulence and kidney pathogenesis of Candida albicans.
PLoS ONE. 7: e48475, 2012.
24)  Roberts DD, Lau LF.
Mecham RP, eds.
Matricellular Proteins. In: Biology of Extracellular Matrix: An Overview.
Berlin Heidelberg: Springer-Verlag; 2011. p. 369-413 [Book Chapter]
25)  Roberts DD.
Activate Rac to rescue new vessels.
Blood. 117: 1444-5, 2011.
26)  Frazier EP, Isenberg JS, Shiva S, Zhao L, Schlesinger P, Dimitry J, Abu-Asab MS, Tsokos M, Roberts DD, Frazier WA.
Age-dependent regulation of skeletal muscle mitochondria by the thrombospondin-1 receptor CD47.
Matrix Biol. 30: 154-61, 2011.
27)  Peterson AW, Pendrak ML, Roberts DD.
ATP binding to hemoglobin response gene 1 protein is necessary for regulation of the mating type locus in Candida albicans.
J. Biol. Chem. 286: 13914-24, 2011.
28)  Kaur S, Roberts DD.
CD47 applies the brakes to angiogenesis via vascular endothelial growth factor receptor-2.
Cell Cycle. 10: 10-2, 2011.
29)  Navarathna DH, Das A, Morschhäuser J, Nickerson KW, Roberts DD.
Dur3 is the major urea transporter in Candida albicans and is co-regulated with the urea amidolyase Dur1,2.
Microbiology. 157: 270-9, 2011.
30)  Roberts DD.
Emerging functions of matricellular proteins.
Cell. Mol. Life Sci. 68: 3133-6, 2011.
31)  Kaur S, Kuznetsova SA, Pendrak ML, Sipes JM, Romeo MJ, Li Z, Zhang L, Roberts DD.
Heparan sulfate modification of the transmembrane receptor CD47 is necessary for inhibition of T cell receptor signaling by thrombospondin-1.
J. Biol. Chem. 286: 14991-5002, 2011.
32)  Pendrak ML, Roberts DD.
Ribosomal RNA processing in Candida albicans.
RNA. 17: 2235-48, 2011.
33)  Martin-Manso G, Calzada MJ, Chuman Y, Sipes JM, Xavier CP, Wolf V, Kuznetsova SA, Rubin JS, Roberts DD.
sFRP-1 binds via its netrin-related motif to the N-module of thrombospondin-1 and blocks thrombospondin-1 stimulation of MDA-MB-231 breast carcinoma cell adhesion and migration.
Arch. Biochem. Biophys. 509: 147-56, 2011.
34)  Soto-Pantoja DR, Isenberg JS, Roberts DD.
Therapeutic Targeting of CD47 to Modulate Tissue Responses to Ischemia and Radiation.
J Genet Syndr Gene Ther. 2, 2011.
35)  Yao M, Roberts DD, Isenberg JS.
Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP.
Pharmacol. Res. 63: 13-22, 2011.
36)  Isenberg JS, Frazier WA, Roberts DD.
Ignarro LJ, eds.
Nitric Oxide Signaling in Vascular Cells is Regulated through CD47 by Thrombospondin-1. In: Nitric Oxide.
Burlington, MA: Elsevier Inc; 2010. p. 415-440 [Book Chapter]
37)  Shi Q, Nguyen AT, Angell Y, Deng D, Na C, Burgess K, Roberts DD, Brunicardi FC, Templeton NS.
A combinatorial approach for targeted delivery using small molecules and reversible masking to bypass nonspecific uptake in vivo.
Gene Therapy. 17: 1085-97, 2010.
38)  Miller TW, Isenberg JS, Shih HB, Wang Y, Roberts DD.
Amyloid-β inhibits No-cGMP signaling in a CD36- and CD47-dependent manner.
PLoS ONE. 5: e15686, 2010.
39)  Ptaszynska MM, Pendrak ML, Stracke ML, Roberts DD.
Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration.
Mol. Cancer Res. 8: 309-21, 2010.
40)  Navarathna DH, Roberts DD.
Candida albicans heme oxygenase and its product CO contribute to pathogenesis of candidemia and alter systemic chemokine and cytokine expression.
Free Radic. Biol. Med. 49: 1561-73, 2010.
41)  Frazier WA, Isenberg JS, Kaur S, Roberts DD.
Nature Signaling Gateway. doi:10.1038/mp.a002870.01, 2010.
Full Text Article. [Journal]
42)  Moody TW, Switzer C, Santana-Flores W, Ridnour LA, Berna M, Thill M, Jensen RT, Sparatore A, Del Soldato P, Yeh GC, Roberts DD, Giaccone G, Wink DA.
Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells.
Lung Cancer. 68: 154-60, 2010.
43)  Navarathna DH, Harris SD, Roberts DD, Nickerson KW.
Evolutionary aspects of urea utilization by fungi.
FEMS Yeast Res. 10: 209-13, 2010.
44)  Valera VA, Li-Ning-T E, Walter BA, Roberts DD, Linehan WM, Merino MJ.
Protein expression profiling in the spectrum of renal cell carcinomas.
J Cancer. 1: 184-96, 2010.
45)  Jourd'heuil D, Lancaster JR, Fukuto J, Roberts DD, Miranda KM, Mayer B, Grisham MB, Wink DA.
The bell-shaped curve for peroxynitrite-mediated oxidation and nitration of NO/O2-* is alive and well.
J. Biol. Chem. 285: le15; author reply le16, 2010.
46)  Jia Y, Wu S, Isenberg JS, Dai S, Sipes JM, Field L, Zeng B, Bandle RW, Ridnour LA, Wink DA, Ramchandran R, Karger BL, Roberts DD.
Thiolutin inhibits endothelial cell adhesion by perturbing Hsp27 interactions with components of the actin and intermediate filament cytoskeleton.
Cell Stress Chaperones. 15: 165-81, 2010.
47)  Kaur S, Martin-Manso G, Pendrak ML, Garfield SH, Isenberg JS, Roberts DD.
Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47.
J. Biol. Chem. 285: 38923-32, 2010.
48)  Miller TW, Isenberg JS, Roberts DD.
Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase.
Br. J. Pharmacol. 159: 1542-7, 2010.
49)  Bauer EM, Qin Y, Miller TW, Bandle RW, Csanyi G, Pagano PJ, Bauer PM, Schnermann J, Roberts DD, Isenberg JS.
Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation.
Cardiovasc Res. 88: 471-81, 2010.
50)  Ghosh S, Navarathna DH, Roberts DD, Cooper JT, Atkin AL, Petro TM, Nickerson KW.
Arginine-induced germ tube formation in Candida albicans is essential for escape from murine macrophage line RAW 264.7.
Infect. Immun. 77: 1596-605, 2009.
51)  Isenberg JS, Annis DS, Pendrak ML, Ptaszynska M, Frazier WA, Mosher DF, Roberts DD.
Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses.
J. Biol. Chem. 284: 1116-25, 2009.
52)  Switzer CH, Ridnour LA, Cheng RY, Sparatore A, Del Soldato P, Moody TW, Vitek MP, Roberts DD, Wink DA.
Dithiolethione compounds inhibit Akt signaling in human breast and lung cancer cells by increasing PP2A activity.
Oncogene. 28: 3837-46, 2009.
53)  Macdonald CJ, Cheng RY, Roberts DD, Wink DA, Yeh GC.
Modulation of carcinogen metabolism by nitric oxide-aspirin 2 is associated with suppression of DNA damage and DNA adduct formation.
J. Biol. Chem. 284: 22099-22107, 2009.
54)  Miller TW, Isenberg JS, Roberts DD.
Molecular Regulation of Tumor Angiogenesis and Perfusion via Redox Signaling.
Chem. Rev. 109: 3099-3124, 2009.
55)  Bass SE, Sienkiewicz P, Macdonald CJ, Cheng RY, Sparatore A, Del Soldato P, Roberts DD, Moody TW, Wink DA, Yeh GC.
Novel dithiolethione-modified nonsteroidal anti-inflammatory drugs in human hepatoma HepG2 and colon LS180 cells.
Clin. Cancer Res. 15: 1964-72, 2009.
56)  Koh E, Bandle RW, Roberts DD, Stracke ML, Clair T.
Novel point mutations attenuate autotaxin activity.
Lipids Health Dis. 8: 4, 2009.
57)  Valera VA, Walter BA, Linehan WM, Roberts DD, Merino MM.
Proteomic analysis of formalin-fixed paraffin embedded (FFPE) samples: pitfalls and potentials.
Curr. Proteomics. 6: 122-139, 2009.
58)  Maxhimer JB, Soto-Pantoja DR, Ridnour LA, Shih HB, Degraff WG, Tsokos M, Wink DA, Isenberg JS, Roberts DD.
Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling.
Sci Transl Med. 1: 3ra7, 2009.
59)  Isenberg JS, Martin-Manso G, Maxhimer JB, Roberts DD.
Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies.
Nat. Rev. Cancer. 9: 182-94, 2009.
60)  Isenberg JS, Qin Y, Maxhimer JB, Sipes JM, Despres D, Schnermann J, Frazier WA, Roberts DD.
Thrombospondin-1 and CD47 regulate blood pressure and cardiac responses to vasoactive stress.
Matrix Biol. 28: 110-9, 2009.
61)  Maxhimer JB, Shih HB, Isenberg JS, Miller TW, Roberts DD.
Thrombospondin-1/CD47 blockade following ischemia-reperfusion injury is tissue protective.
Plast. Reconstr. Surg. 124: 1880-9, 2009.
62)  Isenberg JS, Frazier WA, Roberts DD.
Templeton NS, eds.
In vivo applications of morpholino oligonucleotides. In: Cell and Gene Therapy.
Boca Raton: CRC Press; 2008. p. 478-496 [Book Chapter]
63)  Isenberg JS, Pappan LK, Romeo MJ, Abu-Asab M, Tsokos M, Wink DA, Frazier WA, Roberts DD.
Blockade of thrombospondin-1-CD47 interactions prevents necrosis of full thickness skin grafts.
Ann. Surg. 247: 180-90, 2008.
64)  Calzada MJ, Kuznetsova SA, Sipes JM, Rodrigues RG, Cashel JA, Annis DS, Mosher DF, Roberts DD.
Calcium indirectly regulates immunochemical reactivity and functional activities of the N-domain of thrombospondin-1.
Matrix Biol. 27: 339-51, 2008.
65)  Isenberg JS, Roberts DD, Frazier WA.
CD47: a new target in cardiovascular therapy.
Arterioscler. Thromb. Vasc. Biol. 28: 615-21, 2008.
66)  Dai S, Jia Y, Wu S, Isenberg JS, Ridnour LA, Bandle RW, Wink DA, Roberts DD, Karger BL.
Comprehensive Characterization of Heat Shock Protein 27 Phosphorylation in Human Endothelial Cells Stimulated by the Microbial Dithiole Thiolutin.
J. Proteome Res. 7: 4384-4395, 2008.
67)  Isenberg JS, Yu C, Roberts DD.
Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells.
Biochem. Pharmacol. 75: 875-82, 2008.
68)  Isenberg JS, Frazier WA, Krishna MC, Wink DA, Roberts DD.
Enhancing cardiovascular dynamics by inhibition of thrombospondin-1/CD47 signaling.
Curr Drug Targets. 9: 833-41, 2008.
69)  Isenberg JS, Romeo MJ, Maxhimer JB, Smedley J, Frazier WA, Roberts DD.
Gene silencing of CD47 and antibody ligation of thrombospondin-1 enhance ischemic tissue survival in a porcine model: implications for human disease.
Ann. Surg. 247: 860-8, 2008.
70)  Ridnour LA, Thomas DD, Switzer C, Flores-Santana W, Isenberg JS, Ambs S, Roberts DD, Wink DA.
Molecular mechanisms for discrete nitric oxide levels in cancer.
Nitric Oxide. 19: 73-6, 2008.
71)  Ptaszynska MM, Pendrak ML, Bandle RW, Stracke ML, Roberts DD.
Positive feedback between vascular endothelial growth factor-A and autotaxin in ovarian cancer cells.
Mol. Cancer Res. 6: 352-63, 2008.
72)  Zhao C, Fernandes MJ, Prestwich GD, Turgeon M, Di Battista J, Clair T, Poubelle PE, Bourgoin SG.
Regulation of lysophosphatidic acid receptor expression and function in human synoviocytes: implications for rheumatoid arthritis?.
Mol. Pharmacol. 73: 587-600, 2008.
73)  Kaur S, Samant GV, Pramanik K, Loscombe PW, Pendrak ML, Roberts DD, Ramchandran R.
Silencing of directional migration in roundabout4 knockdown endothelial cells.
BMC Cell Biol. 9: 61, 2008.
74)  Thomas DD, Ridnour LA, Isenberg JS, Flores-Santana W, Switzer CH, Donzelli S, Hussain P, Vecoli C, Paolocci N, Ambs S, Colton CA, Harris CC, Roberts DD, Wink DA.
The chemical biology of nitric oxide: implications in cellular signaling.
Free Radic. Biol. Med. 45: 18-31, 2008.
75)  Isenberg JS, Hyodo F, Ridnour LA, Shannon CS, Wink DA, Krishna MC, Roberts DD.
Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.
Neoplasia. 10: 886-96, 2008.
76)  Martin-Manso G, Galli S, Ridnour LA, Tsokos M, Wink DA, Roberts DD.
Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells.
Cancer Res. 68: 7090-9, 2008.
77)  Isenberg JS, Maxhimer JB, Hyodo F, Pendrak ML, Ridnour LA, DeGraff WG, Tsokos M, Wink DA, Roberts DD.
Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury.
Am. J. Pathol. 173: 1100-12, 2008.
78)  Isenberg JS, Romeo MJ, Yu C, Yu CK, Nghiem K, Monsale J, Rick ME, Wink DA, Frazier WA, Roberts DD.
Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling.
Blood. 111: 613-23, 2008.
79)  Isenberg JS, Frazier WA, Roberts DD.
Thrombospondin-1: a physiological regulator of nitric oxide signaling.
Cell. Mol. Life Sci. 65: 728-42, 2008.
80)  Roberts DD.
Thrombospondins: from structure to therapeutics.
Cell. Mol. Life Sci. 65: 669-71, 2008.
81)  Isenberg JS, Maxhimer JB, Powers P, Tsokos M, Frazier WA, Roberts DD.
Treatment of liver ischemia-reperfusion injury by limiting thrombospondin-1/CD47 signaling.
Surgery. 144: 752-61, 2008.
82)  Kuznetsova SA, Mahoney DJ, Martin-Manso G, Ali T, Nentwich HA, Sipes JM, Zeng B, Vogel T, Day AJ, Roberts DD.
TSG-6 binds via its CUB_C domain to the cell-binding domain of fibronectin and increases fibronectin matrix assembly.
Matrix Biol. 27: 201-10, 2008.
Click Here to View Collapsed Bibliography.

This page was last updated on 6/25/2014.